Accenture, a global management consulting, technology services and outsourcing company, has launched the Accenture Accelerated R&D Services, a business service focused on delivering streamlined and integrated R&D functions to help pharmaceutical companies bring new medications to patients using a more collaborative approach. Accenture is investing more than $200 million to deliver this fully-integrated, technology-enabled global business service.
Accelerated R&D Services will leverage capabilities of the cloud, mobility and analytics to deliver integrated functions across clinical development, regulatory submissions, pharmacovigilance and market launch predicated on delivering better patient outcomes. The services helps life sciences companies bring drugs to market faster, at less cost and with reduced execution risks using a pay-for-performance business model for business process outsourcing.
The business service encompasses clinical services that focus on the traditional “pain points” of effectively identifying the right patients, helping efficient capture of clinical trial data and streamlining the process between data capture and reporting, by leveraging the latest Clinical Data Interchange Standards Consortium (CDISC) criteria, as well as pharmacovigilance services leveraging mobile and web-based data capture. These will drive compliance with new regulations to increase productivity and improve quality in the pharmacovigilance processes and finally integrated cloud-based regulatory services, leveraging CDISC standards and the industry’s integrated cloud-based processing platform to improve regulatory quality, speed and operational efficiency.
“An industry demand exists for new benchmarks that are driven by increasingly stringent health authority requirements, unsustainable fixed-cost models and the complexity of managing numerous vendor partners and technology systems,” said David Boath, senior managing director, Life Sciences Accelerated R&D Services, Accenture.
Accenture is working with key associations such as CDISC and Transcelerate BioPharma to advance industry-wide clinical data standards, streamline research processes and encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies.
